Biomimetic
-
Biologics
3D printing steers walking bio-bots to march of progress
Biomimetics—the use of designs and systems found in nature to inspire engineering solutions—has been a fertile field of innovation. A…
Read More » -
FDA approval of BioMimetic’s Augment Bone Graft dependent on more information
In a post-panel response letter, the FDA told BioMimetic Therapeutics Inc. that it would need to submit more information about…
Read More » -
FDA seeks more info from BioMimetic
BioMimetic Therapeutics Inc. (Nasdaq: BMTI) was dealt a setback Tuesday when it learned the Food and Drug Administration did not approve its application…
Read More » -
BioMimetic Therapeutics’ Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Committee
Franklin, Tenn. – May 12, 2011 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and…
Read More » -
Biologics
BioMimetic Therapeutics Augment™ Bone Graft Advisory Panel Meeting Date Published in Federal Register
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products…
Read More » -
Biomimetic patch to be tested on tricky tendon-to-bone repairs
Group receives more than $2 million to improve surgery for a common shoulder problem IMAGE: A graded biomimetic patch is…
Read More » -
BioMimetic Therapeutics, Inc. Highlights Commercial and Product Development Activities during AAOS
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced highlights from its analyst and investor meeting which was held on…
Read More » -
Biologics
BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment™ Bone Graft
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative drug-device combination…
Read More » -
Biologics
BioMimetic Therapeutics, Inc. Continues to Enhance Patent Portfolio
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No.…
Read More » -
BioMimetic Therapeutics, Inc. Initiates Augment™ Rotator Cuff Graft Trial
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it initiated enrollment in a pilot clinical trial to assess the…
Read More » -
BioMimetic Therapeutics, Inc. to Present at the Canaccord Genuity Global Growth Conference
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel E. Lynch, president and CEO, will provide an…
Read More » -
BioMimetic raises $45 million from stock offering, plans to fund product development
FRANKLIN, Tenn. (AP) – BioMimetic Therapeutics Inc. said it generated about $45 million in proceeds after expenses from the sale…
Read More » -
BioMimetic Therapeutics Receives Filing Letter from FDA for Augment™ Bone Graft PMA
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Food & Drug Administration (FDA) has accepted for review its…
Read More » -
BioMimetic Therapeutics Announces Highlights from 2010 Annual Meeting of Stockholders
FRANKLIN, Tenn., Jun 17, 2010 (BUSINESS WIRE) — BioMimetic Therapeutics, Inc. (BMTI 12.64, +0.19, +1.53%)today announced the results of its 2010 Annual Meeting…
Read More » -
BioMimetic Therapeutics, Inc. to Highlight Pre-Clinical and Clinical Activities at ORS and AAOS Meetings
FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced its schedule of events at the Orthopedic Research Society (ORS) and…
Read More »